Subsequent subcutaneous immunization with irradiated autologous tumor cells containing the retrovirus-delivered IFN-γ enhances the humoral immune response post-immunization and further stimulates the presentation of tumor antigens to the patient’s immune system. This evidence concerns the gene IFNG and neoplasm.